VISEN Pharmaceuticals Deepens Innovative Pipeline through Strategic AI-Driven Collaboration with XtalPi in Endocrine Drug Discovery

On February 5, 2026, VISEN Pharmaceuticals (2561.HK) and XtalPi (2228.HK) jointly announced the achievement of a project agreement and long-term strategic cooperation. The overall scale of this collaboration reaches tens of millions of yuan, focusing on research and development stage objectives and advancing in an orderly manner according to key milestones. VISEN Pharmaceuticals has taken a crucial step in its strategy to explore new R&D paradigms, aiming to deeply integrate cutting-edge technologies such as XtalPi's artificial intelligence (AI) into the source innovation process of its endocrine new drugs. It will continue to focus on indications and innovative targets in the field of endocrine metabolism with high clinical value, carry out early-stage new drug research and development, and accelerate the construction of a more competitive product pipeline.

This collaboration represents VISEN Pharmaceuticals' precise strategic move to further enrich and deepen the breadth and depth of its endocrinology and metabolism pipeline, building on its solid internal R&D capabilities and the introduction of a mature product portfolio. While continuously strengthening internal R&D capabilities and importing established pipelines, the company is proactively incorporating AI-driven original innovation as a key complement. Through in-depth synergy with XtalPi's platform, VISEN Pharmaceuticals aims to break through the bottlenecks of efficiency and success rates inherent in traditional R&D models, injecting new and diversified innovative momentum into its endocrinology and metabolism treatment pipeline.

As an innovative pharmaceutical company focused on the field of endocrine therapy, VISEN Pharmaceuticals has established a full-chain layout covering R&D, production, and sales. Based on a profound understanding of the clinical needs in endocrine diseases and long-term pipeline development planning, VISEN Pharmaceuticals recognizes that to continuously lead innovation in this field and deepen its product pipeline in the endocrine metabolism sector, it is necessary to explore potential new targets, expand indications, as well as upgrade existing pipelines to enhance drug efficacy and safety. Introducing transformative tools like AI technology in the early discovery phase can provide new tools and possibilities to help achieve these two goals. According to CB Insights data, AI technology can reduce the time for drug discovery and preclinical research by nearly 40%, save 50%-60% of the time in the clinical trial phase, and lower R&D costs by approximately 16%.

Specifically, the mechanisms of endocrine and metabolic diseases are complex, especially for certain rare disease targets. Traditional R&D models face challenges such as long cycles and high uncertainty. To address this, VISEN Pharmaceuticals has actively evaluated and introduced AI drug discovery platforms that have been rigorously validated by top pharmaceutical companies worldwide. For instance, XtalPi is collaborating with 17 of the top 20 global pharmaceutical companies; its AI platform accelerated the development of Pfizer’s COVID-19 oral drug PAXLOVID. Its ability to significantly enhance R&D certainty through a "computation + experimentation" closed loop aligns closely with VISEN Pharmaceuticals’ goals of tackling complex targets and pursuing "best-in-class" drugs.

VISEN Pharmaceuticals Chooses to Collaborate with XtalPi for Its Technological Platform, Which Has the Proven Expertise in Serving the World’s Leading Pharmaceutical Companies. The Collaboration Will Focus on the Field of Endocrine and Metabolic Treatments, Leveraging the Combined Technical Advantages of Algorithm-Driven Design and Robotic Experimental Validation to Achieve Early Discovery and Optimization of Novel Molecular Candidates, Systematically Reducing Subsequent R&D Risks.

In China, in terms of the industrial environment, the reform of the review and approval system for pharmaceuticals and medical devices has been continuously deepened in recent years. With policy support, domestic pharmaceutical companies have shifted from simple technology introduction to deep integration with global top platforms, forming R&D capabilities with independent intellectual property rights, providing a good industrial foundation for this kind of cross-border collaboration.

In the future, with the advancement of cooperative projects, more innovative drugs with clinical value are expected to emerge in the field of endocrinology and metabolism, providing patients with more treatment options. This collaboration, which focuses on niche sectors and addresses R&D challenges through technological synergy, will also offer the industry more practical and globally applicable therapies originating from Chinese innovation.